J M Gallego-Escuredo1, J Gómez-Ambrosi2, V Catalan2, P Domingo3, M Giralt1, G Frühbeck2, F Villarroya1. 1. 1] Department of Biochemistry and Molecular Biology and Institute of Biomedicina, University of Barcelona, Barcelona, Spain [2] CIBER Fisiopatología de la Obesidad y Nutrición, Nutrición, Spain. 2. 1] CIBER Fisiopatología de la Obesidad y Nutrición, Nutrición, Spain [2] Clínica Universidad de Navarra, Pamplona, Spain. 3. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Abstract
OBJECTIVE: Fibroblast growth factor (FGF)-21, and possibly FGF19, protect against type 2 diabetes mellitus (T2DM) and obesity in rodents. We investigated the circulating levels of FGF21 and FGF19 in obese patients with varying degrees of abnormal glucose homeostasis, and we determined gene expression for FGF receptors (FGFR1-4) and the co-receptor β-Klotho, in liver and adipose tissues. SUBJECTS AND METHODS: We analyzed 35 lean healthy (71% men) and 61 obese patients (49% men, median body mass index (BMI): 40.5 kg m(-2), interquartile range: 34.7-46.2). Among obese patients, 36 were normoglycemic, 15 showed impaired glucose tolerance and 10 had T2DM. Biopsies from liver and visceral and subcutaneous fat from a subset of obese patients and controls were analyzed. FGF19 and FGF21 levels were measured using enzyme-linked immunosorbent assay, and tissue mRNA and protein levels by reverse transcription-polymerase chain reaction and immunoblotting. RESULTS: FGF21 serum levels were significantly increased in obese patients compared with controls (P<0.001), whereas FGF19 levels were decreased (P < 0.001). FGF21 levels were positively correlated with homeostasis model assessment of insulin resistance (P = 0.0002, r = 0.37) and insulin (P = 0.001, r = 0.32), whereas FGF19 levels were negatively correlated (P = 0.007, r = -0.27; P=0.003, r = -0.28; respectively). After adjusting for BMI, the correlations of FGF21 and FGF19 levels with indicators of abnormal glucose homeostasis were not significant. In obese patients, the hepatic expression of FGF21 was increased. (P = 0.04). β-Klotho transcript levels in visceral fat (P = 0.002) and β-Klotho protein levels in subcutaneous (P = 0.03) and visceral fat (P = 0.04) were significantly reduced in obese patients, whereas hepatic levels for β-Klotho (P = 0.03), FGFR1 (P = 0.04) and FGFR3 (P = 0.001) transcripts were significantly increased. CONCLUSIONS: Obesity is characterized by reciprocal alterations in FGF19 (decrease) and FGF21 (increase) levels. Although worsened in diabetic obese patients, obesity itself appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in β-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity.
OBJECTIVE:Fibroblast growth factor (FGF)-21, and possibly FGF19, protect against type 2 diabetes mellitus (T2DM) and obesity in rodents. We investigated the circulating levels of FGF21 and FGF19 in obesepatients with varying degrees of abnormal glucose homeostasis, and we determined gene expression for FGF receptors (FGFR1-4) and the co-receptor β-Klotho, in liver and adipose tissues. SUBJECTS AND METHODS: We analyzed 35 lean healthy (71% men) and 61 obesepatients (49% men, median body mass index (BMI): 40.5 kg m(-2), interquartile range: 34.7-46.2). Among obesepatients, 36 were normoglycemic, 15 showed impaired glucose tolerance and 10 had T2DM. Biopsies from liver and visceral and subcutaneous fat from a subset of obesepatients and controls were analyzed. FGF19 and FGF21 levels were measured using enzyme-linked immunosorbent assay, and tissue mRNA and protein levels by reverse transcription-polymerase chain reaction and immunoblotting. RESULTS:FGF21 serum levels were significantly increased in obesepatients compared with controls (P<0.001), whereas FGF19 levels were decreased (P < 0.001). FGF21 levels were positively correlated with homeostasis model assessment of insulin resistance (P = 0.0002, r = 0.37) and insulin (P = 0.001, r = 0.32), whereas FGF19 levels were negatively correlated (P = 0.007, r = -0.27; P=0.003, r = -0.28; respectively). After adjusting for BMI, the correlations of FGF21 and FGF19 levels with indicators of abnormal glucose homeostasis were not significant. In obesepatients, the hepatic expression of FGF21 was increased. (P = 0.04). β-Klotho transcript levels in visceral fat (P = 0.002) and β-Klotho protein levels in subcutaneous (P = 0.03) and visceral fat (P = 0.04) were significantly reduced in obesepatients, whereas hepatic levels for β-Klotho (P = 0.03), FGFR1 (P = 0.04) and FGFR3 (P = 0.001) transcripts were significantly increased. CONCLUSIONS:Obesity is characterized by reciprocal alterations in FGF19 (decrease) and FGF21 (increase) levels. Although worsened in diabetic obesepatients, obesity itself appears as the predominant determinant of the abnormalities in FGF21 and FGF19 levels. Opposite changes in β-Klotho expression in fat and liver indicate potential tissue-specific alterations in the responsiveness to endocrine FGFs in obesity.
Authors: Knut Mai; Franziska Schwarz; Thomas Bobbert; Janin Andres; Anke Assmann; Andreas F H Pfeiffer; Joachim Spranger Journal: Metabolism Date: 2010-04-01 Impact factor: 8.694
Authors: Fredirick L Mashili; Reginald L Austin; Atul S Deshmukh; Tomas Fritz; Kenneth Caidahl; Katrin Bergdahl; Juleen R Zierath; Alexander V Chibalin; David E Moller; Alexei Kharitonenkov; Anna Krook Journal: Diabetes Metab Res Rev Date: 2011-03 Impact factor: 4.876
Authors: Serkan Kir; Sara A Beddow; Varman T Samuel; Paul Miller; Stephen F Previs; Kelly Suino-Powell; H Eric Xu; Gerald I Shulman; Steven A Kliewer; David J Mangelsdorf Journal: Science Date: 2011-03-25 Impact factor: 47.728
Authors: Thomas Bobbert; Franziska Schwarz; Antje Fischer-Rosinsky; Andreas F H Pfeiffer; Matthias Möhlig; Knut Mai; Joachim Spranger Journal: Diabetes Care Date: 2012-08-28 Impact factor: 19.112
Authors: Alberto O Chavez; Marjorie Molina-Carrion; Muhammad A Abdul-Ghani; Franco Folli; Ralph A Defronzo; Devjit Tripathy Journal: Diabetes Care Date: 2009-06-01 Impact factor: 19.112
Authors: M Murphy; R Samms; A Warner; M Bolborea; P Barrett; M J Fowler; J M Brameld; K Tsintzas; A Kharitonenkov; A C Adams; T Coskun; F J P Ebling Journal: J Neuroendocrinol Date: 2013-02 Impact factor: 3.627
Authors: A B Crujeiras; D Gomez-Arbelaez; M A Zulet; M C Carreira; I Sajoux; D de Luis; A I Castro; J Baltar; I Baamonde; A Sueiro; M Macias-Gonzalez; D Bellido; F J Tinahones; J A Martinez; F F Casanueva Journal: Int J Obes (Lond) Date: 2017-06-07 Impact factor: 5.095
Authors: Ricardo J Samms; Jo E Lewis; Luke Norton; Francis B Stephens; Christopher J Gaffney; Tony Butterfield; Dennis P Smith; Christine C Cheng; James W Perfield; Andrew C Adams; Francis J P Ebling; Kostas Tsintzas Journal: J Clin Endocrinol Metab Date: 2017-10-01 Impact factor: 5.958
Authors: D Sánchez-Infantes; J M Gallego-Escuredo; M Díaz; G Aragonés; G Sebastiani; A López-Bermejo; F de Zegher; P Domingo; F Villarroya; L Ibáñez Journal: Int J Obes (Lond) Date: 2015-01-20 Impact factor: 5.095
Authors: Z M Gambacorti-Passerini; C López-De la Manzanara Cano; C Pérez Parra; M C Cespedes Casas; L Sánchez Hipólito; C Martín Francisco; J R Muñoz-Rodríguez Journal: Obes Surg Date: 2019-10 Impact factor: 4.129